Aurinia Pharmaceuticals (AUPH) Competitors $12.85 -0.03 (-0.23%) Closing price 04:00 PM EasternExtended Trading$12.73 -0.12 (-0.93%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUPH vs. RYTM, ABVX, CYTK, LEGN, AXSM, NUVL, RNA, MRUS, CRSP, and TGTXShould you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Rhythm Pharmaceuticals (RYTM), Abivax (ABVX), Cytokinetics (CYTK), Legend Biotech (LEGN), Axsome Therapeutics (AXSM), Nuvalent (NUVL), Avidity Biosciences (RNA), Merus (MRUS), CRISPR Therapeutics (CRSP), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Aurinia Pharmaceuticals vs. Its Competitors Rhythm Pharmaceuticals Abivax Cytokinetics Legend Biotech Axsome Therapeutics Nuvalent Avidity Biosciences Merus CRISPR Therapeutics TG Therapeutics Aurinia Pharmaceuticals (NASDAQ:AUPH) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment. Does the media refer more to AUPH or RYTM? In the previous week, Rhythm Pharmaceuticals had 14 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 19 mentions for Rhythm Pharmaceuticals and 5 mentions for Aurinia Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 1.09 beat Aurinia Pharmaceuticals' score of 1.06 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 9 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend AUPH or RYTM? Aurinia Pharmaceuticals presently has a consensus price target of $13.00, suggesting a potential upside of 1.17%. Rhythm Pharmaceuticals has a consensus price target of $105.93, suggesting a potential upside of 6.85%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Rhythm Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 3.06 Is AUPH or RYTM more profitable? Aurinia Pharmaceuticals has a net margin of 23.31% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Aurinia Pharmaceuticals' return on equity of 20.06% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aurinia Pharmaceuticals23.31% 20.06% 13.81% Rhythm Pharmaceuticals -117.13%-1,831.43%-48.33% Do insiders & institutionals have more ownership in AUPH or RYTM? 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, AUPH or RYTM? Aurinia Pharmaceuticals has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500. Which has stronger earnings and valuation, AUPH or RYTM? Aurinia Pharmaceuticals has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurinia Pharmaceuticals$235.13M7.19$5.75M$0.4329.88Rhythm Pharmaceuticals$156.29M42.13-$260.60M-$3.01-32.94 SummaryAurinia Pharmaceuticals beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUPH vs. The Competition Export to ExcelMetricAurinia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.69B$2.49B$5.65B$10.30BDividend YieldN/A56.32%5.68%4.62%P/E Ratio29.8823.2775.8426.11Price / Sales7.19578.02517.39171.57Price / Cash42.15174.1537.5661.52Price / Book4.795.1412.876.30Net Income$5.75M$32.95M$3.29B$271.03M7 Day Performance-0.31%0.10%-0.26%-0.14%1 Month Performance5.85%5.05%3.85%6.42%1 Year Performance78.47%1.04%68.36%28.81% Aurinia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUPHAurinia Pharmaceuticals2.8471 of 5 stars$12.85-0.2%$13.00+1.2%+83.5%$1.69B$235.13M29.88300Positive NewsRYTMRhythm Pharmaceuticals3.1879 of 5 stars$96.03-0.2%$101.57+5.8%+89.1%$6.39B$130.13M0.00140Trending NewsAnalyst ForecastABVXAbivax3.0313 of 5 stars$85.87+2.2%$99.43+15.8%+629.9%$6.35BN/A0.0061Analyst ForecastCYTKCytokinetics4.2065 of 5 stars$49.44-3.3%$75.38+52.5%-8.3%$6.12B$18.47M0.00250Trending NewsAnalyst ForecastAnalyst RevisionLEGNLegend Biotech3.1481 of 5 stars$33.88+2.3%$74.22+119.1%-27.4%$6.11B$627.24M0.002,609Positive NewsAXSMAxsome Therapeutics4.8228 of 5 stars$116.78-1.4%$177.86+52.3%+30.1%$5.91B$385.69M0.00380Insider TradeNUVLNuvalent3.1508 of 5 stars$79.37-1.4%$120.91+52.3%-21.5%$5.80BN/A0.0040Positive NewsRNAAvidity Biosciences2.0019 of 5 stars$40.22-10.1%$68.94+71.4%-1.8%$5.76B$10.90M0.00190Analyst ForecastMRUSMerus2.6966 of 5 stars$68.09-2.1%$88.75+30.3%+43.2%$5.26B$36.13M0.0037Positive NewsCRSPCRISPR Therapeutics3.1647 of 5 stars$57.84+2.8%$71.60+23.8%+30.5%$5.12B$37.31M0.00460Analyst ForecastTGTXTG Therapeutics4.2582 of 5 stars$31.75-1.3%$46.25+45.7%+51.9%$5.10B$329M86.92290 Related Companies and Tools Related Companies RYTM Alternatives ABVX Alternatives CYTK Alternatives LEGN Alternatives AXSM Alternatives NUVL Alternatives RNA Alternatives MRUS Alternatives CRSP Alternatives TGTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUPH) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AUPH Stock Alerts